Suppr超能文献

2018 年加拿大《大麻法案》的影响:医用和非医用大麻的监管是否应该有所不同?

Implications of the 2018 Canadian Cannabis Act: Should regulation differ for medicinal and non-medicinal cannabis use?⋆.

机构信息

University of Ottawa, Faculty of Law (Common Law), Fauteux Hall, 57 Louis Pasteur St., Ottawa, ON K1N6N5, Canada.

出版信息

Health Policy. 2021 Jan;125(1):12-16. doi: 10.1016/j.healthpol.2020.10.016. Epub 2020 Nov 11.

Abstract

The regulatory framework for access to medical cannabis has been established in Canada since 2001, with the number of patients seeking access growing substantially over the years. With the novel enactment of the Cannabis Act in October 2018, Canada now maintains two distinct mechanisms for accessing cannabis - one for medical cannabis and the other for non-medical cannabis. With two regulatory access mechanisms in place, questions have arisen in the country as to the necessity of maintaining regulatory separation and the integrity of the medical access framework. A single framework would remove the gate-keeping function that the medical profession currently holds, streamlining processes and simplifying the current regulatory landscape. This approach has been advocated for by the Canadian Medical Association, despite objections from multiple stakeholders. Critical questions arise should the medical access framework be dissolved into a single, non medical-based regulatory framework. Insurance coverage, control mechanisms, market incentives, and patient obligations represent some examples of these issues. This paper will expand upon these considerations and highlight why maintaining two separate access mechanismss best serves the Canadian public. As medicinal cannabis continues to be liberated in international jurisdictions, this paper can help to illuminate the current status of medical cannabis in Canada, and provide insights to those from other countries on our current approach and domestic challenges.

摘要

自 2001 年以来,加拿大已经建立了医疗大麻准入的监管框架,寻求准入的患者人数多年来大幅增加。随着 2018 年 10 月《大麻法》的新颁布,加拿大现在为获取大麻维持着两种截然不同的机制——一种是医疗用大麻,另一种是非医用大麻。有了这两个监管准入机制,加拿大国内出现了一些问题,例如是否有必要维持监管分离和医疗准入框架的完整性。一个单一的框架将消除医疗行业目前所拥有的把关职能,简化流程,简化当前的监管格局。尽管遭到多个利益相关者的反对,但加拿大医学会还是倡导了这一做法。如果将医疗准入框架融入一个单一的、非医疗为基础的监管框架,就会产生一些关键性问题。保险覆盖范围、控制机制、市场激励措施和患者义务就是其中的一些例子。本文将对这些问题进行扩展,并强调为什么维持两个独立的准入机制最符合加拿大公众的利益。随着药用大麻在国际司法管辖区继续合法化,本文可以帮助阐明加拿大目前医用大麻的现状,并为其他国家提供有关我们目前方法和国内挑战的见解。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验